(1997). A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia.
(2012). Abnormal nuclear envelope in the cerebellar Purkinje cells and impaired motor learning in DYT11 myoclonus-dystonia mouse models.
(2012). Abnormal nuclear envelopes in the striatum and motor deficits in DYT11 myoclonus-dystonia mouse models.
(2012). An anticholinergic reverses motor control and corticostriatal
(1999). Association of a missense change in the D2 dopamine receptor with myoclonus dystonia.
(1990). Autoreceptor regulation of dopamine synthesis.
(2003). Cloning, developmental regulation and neural localization of rat epsilon-sarcoglycan.
(2011). Cocaine supersensitivity and enhanced motivation for reward in mice lacking dopamine D2 autoreceptors.
(1988). Concept and classification of dystonia.
(2010). Control of extracellular dopamine at dendrite and axon terminals.
(2005). Decreased striatal D2 receptor binding in non-manifesting carriers of the DYT1 dystonia mutation.
(2003). Dopamine controls the firing pattern of dopamine neurons via a network feedback mechanism.
(2000). Dopamine D2 long receptor-deficient mice display alterations in striatum-dependent functions.
(1998). Dopamine receptors: from structure to function.
(2007). Dopamine release is impaired in a mouse model of DYT1 dystonia.
(2005). Dopamine responsiveness is regulated by targeted sorting of D2 receptors.
(2010). Earlier onset of motor deficits in mice with double mutations in Dyt1 and Sgce.
(2006). Epsilon sarcoglycan mutations and phenotype in French patients with myoclonic syndromes.
(2005). Epsilonsarcoglycan immunoreactivity and mRNA expression in mouse brain.
(2005). Exclusive paternal expression and novel alternatively spliced variants of epsilon-sarcoglycan mRNA in mouse brain.
(1995). Frequent sequence variant in the human tyrosine hydroxylase gene.
(1994). Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene.
(2011). How addictive drugs disrupt presynaptic dopamine neurotransmission.
(2004). Identification and characterization of epsilon-sarcoglycans in the central nervous system.
(1998). Imaging the pre- and postsynaptic side of striatal dopaminergic synapses in idiopathic cervical dystonia: a SPECT study using [123I] epidepride and [123I] beta-CIT.
(2007). Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine.
(2005). Molecular and cell biology of the sarcoglycan complex.
(2001). Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome.
(2007). Myoclonus-dystonia syndrome with severe depression is caused by an exonskipping mutation in the epsilon-sarcoglycan gene.
(2006). Myoclonus, motor deficits, alterations in emotional responses and monoamine metabolism in epsilon-sarcoglycan deficient mice.
(2011). Nakagawara A
(1995). Nocturnal myoclonus syndrome (periodic movements in sleep) related to central dopamine D2-receptor alteration. Eur Arch Psychiatry Clin Neurosci 245: 8–10. Altered Striatal Dopaminergic Function
(2002). Phenotypic features of myoclonus-dystonia in three kindreds.
(2003). Presynaptic regulation of dopaminergic neurotransmission.
(2006). Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine.
(1995). Recessively inherited L-DOPA-responsive dystonia caused by a point mutation (Q381K) in the tyrosine hydroxylase gene.
(2011). Regulation of G Protein-Coupled Receptor Activity, Trafficking and Localization by Gpcr-Interacting Proteins.
(2011). SGCE isoform characterization and expression in human brain: implications for myoclonus-dystonia pathogenesis?
(2007). SGCE missense mutations that cause myoclonus-dystonia syndrome impair epsilonsarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA.
(2005). Tardive Dystonia.
(2003). The epsilon-sarcoglycan gene (SGCE), mutated in myoclonus-dystonia syndrome, is maternally imprinted.
(2000). Zac1 (Lot1), a potential tumor suppressor gene, and the gene for epsilonsarcoglycan are maternally imprinted genes: identification by a subtractive screen of novel uniparental fibroblast lines.